When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
NVS - Incyte's Jakafi successful in another graft-versus-host disease study
Novartis AG
Incyte (NASDAQ:INCY) announces positive results from a Phase 3 clinical trial, REACH3, evaluating Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GvHD). The study met the primary endpoint demonstrating superior overall response rate compared to best available therapy. Both key secondary endpoints were also met.
More news on: Incyte Corporation, Novartis AG, Healthcare stocks news,